logo-loader

Scancell extends commercial licence with Ichor

Published: 02:19 20 Jul 2016 EDT

A white blood cell
TriGrid allows for the genetic manipulation of a cell using pulses of electricity.

Cancer immunotherapy group Scancell Holdings Plc (LON:SCLP) has extended its commercial licence of Ichor Medical System’s electroporation delivery system, TriGrid for a further two years.

Scancell will continue to use Ichor’s system in conjunction with its flagship melanoma vaccine SCIB1.

TriGrid allows for the genetic manipulation of a cell by using pulses of electricity to momentarily open the pores of the cell membrane.

"Ichor's proprietary TriGrid electroporation delivery system remains central to our studies on SCIB1 and in particular, to our upcoming US clinical study of SCIB1 in combination with a checkpoint inhibitor, expected to commence in 2017,” said chief executive Richard Goodfellow.

In exchange, Scancell has granted a partial two-year waiver over the lock-up which prohibited the sale of Tranche 2 shares, as originally announced in July 2009 and extended in July 2014.

Subject to exercise of the Tranche two share options, Ichor will remain under an orderly market agreement requiring any sale during that two year period to be effected through Scancell's brokers.  

Scancell CEO hails "exciting" high response rate to melanoma treatment

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) chief executive Professor Lindy Durrant speaks to Thomas Warner from Proactive to provide an update on the initial phase of the clinical stage biopharmaceutical company's Phase 2 SCOPE trial in advanced melanoma. Professor Durrant gives an overview...

on 09/19/2023